CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
Dividends
CytomX Therapeutics, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does CytomX Therapeutics, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Xencor, Inc. NASDAQ:XNCR | $2.78B | 0.00% | $0.00 | 0.00% | 0.00% |
Celldex Therapeutics, Inc. NASDAQ:CLDX | $2.26B | 0.00% | $0.00 | 0.00% | 0.00% |
Zymeworks Inc. NASDAQ:ZYME | $1.83B | 0.00% | $0.00 | 0.00% | 9.13% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | 0.00% | $0.00 | 0.00% | 0.00% |
ADC Therapeutics S.A. NYSE:ADCT | $171.07M | 0.00% | $0.00 | 0.00% | 0.14% |
Sutro Biopharma, Inc. NASDAQ:STRO | $162.83M | 0.00% | $0.00 | 0.00% | 0.04% |
Veraxa Biotech Holding AG NASDAQ:VRXA | $156.96M | — | $0.00 | — | 0.00% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | 0.00% | $0.00 | 0.00% | 0.00% |
Pyxis Oncology, Inc. NASDAQ:PYXS | $100.10M | 0.00% | $0.00 | 0.00% | 0.04% |
Adagene Inc. NASDAQ:ADAG | $64.38M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about CTMX's dividend, answered from reported figures.
Does CTMX stock pay dividends?
CytomX Therapeutics, Inc. (CTMX) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is CTMX's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.